CXCL10 and type 2 diabetes mellitus: In vitro and animal studies demonstrate their effectiveness in reducing the release of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interferon gamma-induced protein 10 (IP-10), cytokines often overexpressed in T2DM patients (41, 42).